<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Selection of second-line therapy for chronic lymphocytic leukemia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Selection of second-line therapy for chronic lymphocytic leukemia</h1>
<div class="graphic"><div class="figure"><div class="ttl">Selection of second-line therapy for chronic lymphocytic leukemia</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_lgnd">This algorithm presents our general approach to the selection of second-line therapy for CLL. When choosing between multiple acceptable treatment options, we consider patient characteristics as shown in the inset. Selection of third-line therapy is based on prior treatments received and response to these treatments. Patients who discontinue a therapy due to intolerance may be candidates for treatment with a different agent from the same class as long as mechanism of action interfering mutations are not present. BTK inhibitors and venetoclax-based treatment are used prior to other agents. We reserve PI3K inhibitors for patients with relapsed/refractory CLL with prior exposure to both BTK inhibitors and venetoclax.</div><div class="graphic_footnotes">BTK: Bruton tyrosine kinase; CLL: chronic lymphocytic leukemia; PI3K: phosphoinositide 3'-kinase.</div><div id="graphicVersion">Graphic 129414 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
